The Vanguard ETF That Acts Like a Hedge Fund Without the Fees
Strategic angle: Discover how this Vanguard ETF offers hedge fund-like benefits without the associated costs.
Editorial Staff Apr 6
Investment Funds
Latest Investment Funds stories from Money.
VanEck Rare Earth and Strategic Metals ETF Is Focused on a Hot Sector, Which is Good and Bad
Strategic angle: An analysis of the VanEck ETF's focus on rare earth and strategic metals amidst market volatility.
Editorial Staff Apr 6
Briefing: Sovereign Demand for Minerals Should Keep Lifting This Metals and Mining ETF
Strategic angle: A look at how increasing sovereign demand for minerals is positively impacting a specific metals and mining ETF.
Editorial Staff Mar 31
Briefing: URNM: ETF With Global Exposure In The Uranium Industry
Strategic angle: Exploring the potential of the URNM ETF in the uranium sector.
Editorial Staff Mar 29
Briefing: Private equity turned vulnerable elderly people into human ATMs
Strategic angle: Exploring the exploitation of elderly individuals by private equity firms.
Editorial Staff Mar 28
Briefing: 'Not unlike tariffs': Iran war threatens to deepen Asia private equity's worst fundraising slump in a decade
Strategic angle: The Middle East war has introduced a new layer of uncertainty for Asia-focused private equity managers already navigating a multiyear fundraising slump.
Editorial Staff Mar 27
Briefing: The Best ETF Over The Past 10 Years Turned $10,000 To $65,100
Strategic angle: Discover the top-performing ETF that significantly increased investment returns over the last decade.
Editorial Staff Mar 26
Briefing: Will Vanguard Growth Keep Crushing Its ETF Peers?
Strategic angle: An analysis of Vanguard Growth's performance against other ETFs.
Editorial Staff Mar 25
Briefing: DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing
Strategic angle: DAFNA Capital has made adjustments to its holdings in the iShares Biotechnology ETF as part of a broader strategy in the biotech sector.
Editorial Staff Mar 21
Briefing: A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
Strategic angle: Explore the implications of a significant investment by a hedge fund in Immunovant and what it could mean for potential investors.
Editorial Staff Mar 15
Private Equity's Role in Primary Care: A Balancing Act
Recent findings suggest that while private equity is driving investment in primary care, clinician growth is tempered by a notable increase in exits.
Editorial Staff Mar 8